Beskrivelse
-
Beskrivelse
Ofatumumab (Arzerra
), en intravenøs monoklonalt antistof lægemiddel rettet mod CD20 proteinet på B-celler, blev godkendt af den amerikanske Food and Drug Administration (FDA) fremskyndet processen i oktober 2009 til behandling af kronisk lymfatisk leukæmi (CLL), som er refraktære over for fludarabin og alemtuzumab.Ofatumumab (Arzerra
) er også anerkendt af National Comprehensive Cancer Network (NCCN) til behandling af recidiverende CLL
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind